Minerva Neurosciences | NERV - Чистый доход





Чистый доход Изменить Дата
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Adma Biologics USD 49.38M 12.95M 2025-12
ALKERMES USD 49.34M 33.42M 2025-12
Alterity Therapeutics Limited AUD -6.3M 525.41K 2025-12
AstraZeneca USD 3.08B 754M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Cipla INR 6.76B 6.75B 2025-12
Clal Biotechnology ILS -6.17M 15.56M 2022-12
Compugen USD 56.84M 63.82M 2025-12
CSL USD 401M 96.5M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Esperion Therapeutics USD 61.83M 93.16M 2025-12
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Grifols EUR 114.37M 34.03M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
J&J USD 5.24B 119M 2026-03
Merck USD -4.24B 7.2B 2026-03
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Neurocrine Biosciences USD 153.7M 55.8M 2025-12
Novartis USD 3.16B 747M 2026-03
Novavax USD 17.53M 219.91M 2025-12
Pfizer USD -1.65B 5.19B 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR 1.61B 2.42B 2026-03
Takeda JPY 103.64B 115.44B 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12